Periimplantitis may trigger the development of Medication Related Osteonecrosis of the Jaw in Oncological Patients

2018 ◽  
Author(s):  
Thabet Asbi
Keyword(s):  
Osteonecrosis Of The Jaw ◽  
Oncological Patients

scholarly journals Dental management in Oncology patient: osteonecrosis related osteonecrosis of the Jaw (MRONJ)

2020 ◽  
Vol 4 (1) ◽  
pp. 01-02
Author(s):  
Picardo Noemi
Keyword(s):  
Task Force ◽  
Health Assessment ◽  
Osteonecrosis Of The Jaw ◽  
Oncology Patient ◽  
Stomatognathic System ◽  
Oncological Patients ◽  
Dental Management ◽  
Antiresorptive Drugs ◽  
Antiangiogenic Drugs

It is essential that oncological patients treated with antiresorptives or antiangiogenic drugs diagnosed Medication Related Osteonecrosis of the Jaw (MRONJ) must be treated in an interdisciplinary fashion. The patient’s stomatognathic system should be examined preventatively prior to the initiation of antiresorptive drugs in order to avoid pathological buccal manifestations, following the same healthcare clinical protocols used for patients receiving head and neck radiotherapy. Additionally, patients should be informed of the precautions to be taken, including regular dental appointments for oral health assessment. The risk of developing MRONJ should be evaluated according to the type of antiresorptives or antiangiogenic drugs administered and treatment duration. In the case of MRONJ, its fundamental characteristic is positioned in the biochemical particularity of the pharmacokinetic expression of antiresorptive drugs, reversibly (DS) or irreversibly (BPs) inhibiting the functionality of the osteoclast. Therefore, the consideration of invading bone tissue as little as possible and performing resective therapies in cases of systemic infectious spread follows, since its long-term resolution would not be effective because the drug (BPs) has frank accumulation at a distance, a characteristic used by treating doctors and it would not have clinical relevance to suggest its suspension. According to the recommendations of AAOMS; Task Force and AOCMF coincide with the sharing of consensus on minimally invasive manipulations once the necrotic foci have been installed and the preventive attitude prevails of eliminating all septic foci prophylactically before starting therapy with antiresorptive drugs. There are positions with a trend more committed to frank bone manipulation with the aim of evacuating the infectious problem and other more conservative positions in order not to expand drug necrosis volumetrically due to bone accumulation of BPs or DS.

scholarly journals Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2

2017 ◽  
Vol 55 (8) ◽  
pp. 787-792 ◽  
Author(s):  
R.G. Coropciuc ◽  
K. Grisar ◽  
T. Aerden ◽  
M. Schol ◽  
J. Schoenaers ◽  
...  
Keyword(s):  
Conservative Treatment ◽  
Osteonecrosis Of The Jaw ◽  
Skeletal Metastases ◽  
Oncological Patients

scholarly journals Therapy with bone-modifying agents in cancer patients: Efficacy versus adverse events in dental medicine

2021 ◽  
Vol 67 (1) ◽  
pp. 12-16
Author(s):  
Olimpia Bunta ◽  
◽  
Iulia Najette Crintea ◽  
Andreea Pop ◽  
Adina Nemes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Overall Survival ◽  
Adverse Events ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Preventive Measures ◽  
Osteonecrosis Of The Jaw ◽  
Treatment Results ◽  
Oncological Patients

Bone metastases affect a large number of oncological patients and can determine complications that can impact the quality of life of our patients and further translate into lessen treatment results and overall survival. Treatment with bisphosphonates (BP) has proven its efficacy in preventing the development of the complications related to bone metastases. BP are well tolerated in general but severe adverse events can occur, like osteonecrosis of the jaw (ONJ). Besides ONJ there are other dental and maxillofacial complications determined by BP, complications that by elementary preventive measures can be avoided.

RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN ONCOLOGICAL PATIENTS WITH OSTEONECROSIS OF THE JAW FROM BISPHOSPHONATES

2020 ◽  
Vol 130 (3) ◽  
pp. e255
Author(s):  
ANA RAPHAELA MAIA DEZAN COUTO CURVO ◽  
VICTOR AUGUSTO MINARI ◽  
LARA MARIA ALENCAR RAMOS INNOCENTINI ◽  
HILTON MARCOS ALVES RICZ ◽  
ADRIANO TADEU MARANGONI ◽  
...  
Keyword(s):  
Risk Factors ◽  
Osteonecrosis Of The Jaw ◽  
Infectious Complications ◽  
Oncological Patients

F-18-FDG Positron Imaging in Oncological Patients: Gamma Camera Coincidence Detection versus Dedicated PET

1999 ◽  
Vol 38 (04) ◽  
pp. 108-114 ◽  
Author(s):  
H.-J. Kaiser ◽  
U. Cremerius ◽  
O. Sabri ◽  
M. Schreckenberger ◽  
P. Reinartz ◽  
...  
Keyword(s):  
Attenuation Correction ◽  
Spatial Resolution ◽  
Gamma Camera ◽  
Lesion Detection ◽  
Coincidence Detection ◽  
System Sensitivity ◽  
Oncological Patients ◽  
Phantom Studies ◽  
Pet System ◽  
Dedicated Pet

Summary Aim of the present study was to investigate the feasibility of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) imaging in oncological patients with a dual head gamma camera modified for coincidence detection (MCD). Methods: Phantom studies were done to determine lesion detection at various lesion-to-background ratios, system sensitivity and spatial resolution. Thirty-two patients with suspected or known malignant disease were first studied with a dedicated full-ring PET system (DPET) applying measured attenuation correction and subsequently with an MCD system without attenuation correction. MCD images were first interpreted without knowledge of the DPET findings. In a second reading, MCD and DPET were evaluated simultaneously. Results: The phantom studies revealed a comparable spatial resolution for DPET and MCD (5.9 × 6.3 × 4.2 mm vs. 5.9 × 6.5 × 6.0 mm). System sensitivity of MCD was less compared to DPET (91 cps/Bq/ml/cmF0V vs. 231 cps/ Bq/ml/cmFOv). At a lesion-to-background ratio of 4:1, DPET depicted a minimal phantom lesion of 1.0 cm in diameter, MCD a minimal lesion of 1.6 cm. With DPET, a total of 91 lesions in 27 patients were classified as malignant. MCD without knowledge of DPET results revealed increased FDG uptake in all patients with positive DPET findings. MCD detected 72 out of 91 DPET lesions (79.1 %). With knowledge of the DPET findings, 11 additional lesions were detected (+12%). MCD missed lesions in six patients with relevance for staging in two patients. All lesions with a diameter above 18 mm were detected. Conclusion: MCD FDG imaging yielded results comparable to dedicated PET in most patients. However, a considerable number of small lesions clearly detectable with DPET were not detected by MCD alone. Therefore, MCD cannot yet replace dedicated PET in all oncological FDG studies. Further technical refinement of this new method is needed to improve image quality (e.g. attenuation correction).

Use of 'Korona' cava filter in oncological patients

2019 ◽  
Vol 25 (4) ◽  
pp. 139
Author(s):  
V. A. Cherkasov ◽  
B. I. Dolgushin ◽  
Iu. G. Andreev ◽  
O. V. Somonova
Keyword(s):  
Oncological Patients

Hypercalcaemia and osteonecrosis of the jaw in association with denosumab use in the paediatric population

2019 ◽  
Author(s):  
Christie-Lee Wall ◽  
Verity Pacey ◽  
Kelly Gray ◽  
Richard McGee ◽  
Melissa Fiscaletti ◽  
...  
Keyword(s):  
Paediatric Population ◽  
Osteonecrosis Of The Jaw

The incidence of Bisphosphonate related Osteonecrosis of the Jaw (BONJ) in patients treated with oral bisphosphonates for osteoporosis

2017 ◽  
Author(s):  
Fergus MacLean ◽  
Rebecca Mason ◽  
Jeff Downie ◽  
Iain Watt ◽  
Andrew Gallagher ◽  
...  
Keyword(s):  
Osteonecrosis Of The Jaw ◽  
Oral Bisphosphonates
Sign in / Sign up

Export Citation Format

Share Document